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LiverThe liver isoform of the enzyme alkaline phosphatase (AP) has been used classically as a serum biomarker for
hepatic disease states such as hepatitis, steatosis, cirrhosis, drug-induced liver injury, and hepatocellular carcino-
ma. Recent studies have demonstrated a more general anti-inﬂammatory role for AP, as it is capable of
dephosphorylating potentially deleterious molecules such as nucleotide phosphates, the pathogenic endotoxin
lipopolysaccharide (LPS), and the contact clotting pathway activator polyphosphate (polyP), thereby reducing
inﬂammation and coagulopathy systemically. Yet the mechanism underlying the observed increase in liver AP
levels in circulation during inﬂammatory insults is largely unknown. This paper hypothesizes an immunological
role for AP in the liver and the potential of this system for damping generalized inﬂammation along with a wide
range of ancillary pathologies. Based on the provided framework, a mechanism is proposed in which AP
undergoes transcytosis in hepatocytes from the canalicular membrane to the sinusoidal membrane during
inﬂammation and the enzyme's expression is upregulated as a result. Through a tightly controlled, nucleotide-
stimulated negative feedback process, AP is transported in thismodel as an immune complexwith immunoglob-
ulin G by the asialoglycoprotein receptor through the cell and secreted into the serum, likely using the receptor's
State 1 pathway. The subsequent dephosphorylation of inﬂammatory stimuli by AP and uptake of the circulating
immune complex by endothelial cells and macrophages may lead to decreased inﬂammation and coagulopathy
while providing an early upstream signal for the induction of a number of anti-inﬂammatory gene products,
including AP itself.
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ights reserved.1. Introduction
According to the current ‘danger model’ for immune recognition
and inﬂammatory responses, pathogenic and endogenous stimuli
alike have the capability to induce an immune reaction in the body
[1,2]. Pathogenic insults are referred to as ‘pathogen-associated mo-
lecular patterns’, or PAMPs, and endogenous insults as ‘damage-as-
sociated molecular patterns’, or DAMPs. Both types of molecules
are able to stimulate receptors on multiple cell types known as
pattern-recognition receptors, or PRRs, such as the Toll-like recep-
tors (TLRs) [1–3]. PAMPs are usually encountered upon exposure
to microorganisms, while DAMPs result from generalized tissue
damage and do not necessarily correspond to infection. However,
both signal types, which can be elicited by infection, trauma, hypox-
ia/ischemia, hemorrhagic shock, and numerous other insults, lead to
the same sequences of non-speciﬁc protective and reparative
processes in the body, known collectively as inﬂammation [3,4].
Inﬂammation thus may be pathogen-associated or sterile, and in
either case it may occur locally or, as its severity increases, spread
to become ‘systemic inﬂammatory response syndrome’ (SIRS) [4].
Inﬂammation and aberrant hemostasis are intimately related. For in-
stance, SIRS induces heightened production of pro-inﬂammatory
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systemic coagulation [4,5]. Moreover, inﬂammation due to septic bacte-
rial infection can lead to disseminated intravascular coagulation, or DIC
[6]. Not surprisingly, inﬂammatory liver disease often correlates with
severe hemostatic abnormality which may be pro- or anti-coagulant
[7,8]. Elevated serum levels of the liver isoform of the enzyme alkaline
phosphatase (AP; EC 3.1.3.1) have been associated classically with
inﬂammatory hepatic disease states including chronic hepatitis [9,10],
primary sclerosing cholangitis [11], liver cirrhosis [10,12], cystic ﬁbrosis
[13], and hepatocellular carcinoma [10,14–18]. AP is a well-known
glycosylphosphatidylinositol (GPI)-anchored ecto-phosphomono-
esterase with differential tissue expression and multiple isozymes
and isoforms. APs act to dephosphorylate a number of substrates
which have been implicated speciﬁcally in the promotion of inﬂamma-
tion and coagulopathy through their PAMP or DAMP effects, including
pathogenic lipopolysaccharide (LPS) and endogenous polyphosphate
(polyP) and nucleotide phosphates, respectively [19,20].
Dephosphorylation of such molecules by AP has been linked to
anti-inﬂammatory and anti-thrombotic effects. The bacterial endo-
toxin LPS, for example, can be released into circulation during infec-
tion or upon the disruption of intestinal barrier integrity that
commonly occurs in both ﬁbrotic liver disease and ischemia/reperfu-
sion injury [21,22], triggering a host of potentially lethal inﬂamma-
tory responses mediated by TLR4 signaling (reviewed in [23]). LPS
is also able to trigger the contact pathway of clot formation, which
leads to increased thrombus generation [19,24]. AP-catalyzed de-
phosphorylation of LPS in the lipid A region is known to reduce its
toxic potency [25,26]. This detoxiﬁcation promotes survival during
a systemic LPS challenge in rats [26,27]. AP in the intestine has
been shown to protect mice from luminal bacterial translocation
across the gut mucosal barrier and systemic LPS toxicity after ische-
mia and reperfusion [28,22]. Also, extreme increases in plasma AP
levels accompany E. coli-induced bacteremia in humans [29]. PolyP,
an inorganic phosphate polymer, is found in many microorganisms
and is also released into circulation from activated human platelets
and mast cells [24,30]. PolyP powerfully induces coagulation, throm-
bosis, and inﬂammation as well as capillary leakage in a polymer
length-dependent manner by acting at multiple points along the
clotting cascade [30,31]. AP demonstrates strong exophosphatase
activity on polyP, cleaving individual phosphates from each terminal
of the linear molecule, thereby decreasing the length of the polymer
over time. The end result of this is the inhibition of polyP-induced co-
agulation and inﬂammation [24,30]. Endogenous adenosine nucleo-
tides such as ATP can be released lytically or non-lytically from
hepatocytes and other cell types into the extracellular environment
in response to various inﬂammatory stimuli, triggering anti-
inﬂammatory signaling cascades through high-afﬁnity P2Y receptors
and, at higher concentrations, pro-inﬂammatory signaling cascades
through low-afﬁnity P2X receptors on the membranes of neighb-
oring cells [32–37,111]. ATP and ADP-induced pro-inﬂammatory
processes include vasodilation and prothrombotic signaling, and
serum concentrations of ADP are key in the regulation of platelet
activation [38], resulting in polyP release and subsequent triggering
of the contact pathway [39]. AP has the unique ability to remove
phosphates sequentially from ATP and ADP, thereby keeping the
levels of these nucleotides in check and helping to promote anti-
inﬂammatory P2Y signaling while simultaneously generating
the purine adenosine [40], which induces a widespread anti-
inﬂammatory effect via P1 receptor signaling [32].
It has been found recently that clinical bolus treatment followed by
continuous infusion with exogenous bovine intestinal AP (biAP) de-
creases the incidence of post-operative systemic inﬂammation in coro-
nary artery bypass graft (CABG) patients [41]. Similar decreases in levels
of pro-inﬂammatory cytokines have been observed at a later stage in the
inﬂammatory process in dialysis patients with severe sepsis-induced
acute kidney injury [42,43]. Based on outcomes such as these, AP isattracting renewed attention for its potential as a therapeutic agent in
the prevention and treatment of generalized inﬂammation.
Treatment of rat liver slices with biAP was shown to induce endog-
enous production of liver APmRNAwithin 2 h [41]. Clinical administra-
tion of intravenous biAP in CABG patients induced an initial peak in
plasma AP concentration followed by a sharp decrease due to liver up-
take; this was counteracted unexpectedly by a subsequent increase in
plasma concentrations of tissue non-speciﬁc AP (TNAP) from the liver,
detected 4–6 h after surgery [44]. The exact mechanism underlying
these observations of TNAP expression and secretion from the liver in
response to exogenous biAP remains unknown. A sensitive negative
feedback model for the expression of AP on apical membranes of polar-
ized cells involving ecto-purinergic P2Y receptor activation by ATP and
pH control by bicarbonate has been proposed for many polarized epi-
thelia [45–47], including liver parenchymal cells [48]. It is known that
endogenous AP is expressed at the hepatocyte canalicular membrane,
and also that exogenous circulating asialo-AP is cleared by the liver
through uptake by the asialoglycoprotein receptor (ASGP-R) from the
sinusoidal membrane [41,49]. However, it is still unclear how newly
synthesized AP on the canalicular membrane might be delivered
along the opposite trajectory to the circulation in response to an inﬂam-
matory threat or to detection of AP in the serum, and whether or not
thismechanismmight involve transport of AP by the ASGP-R or another
receptor.
The ASGP-R (reviewed in [50–54]) binds to an assortment of circu-
lating asialoglycoproteins [52,55]. The receptor has two subpopulations,
known as State 2 and State 1 receptors,which followdifferent pathways
as they transport and process their ligands. While there are relatively
equal numbers of receptors in each category, State 2 receptors are sig-
niﬁcantly more active in terms of ligand uptake and degradation than
are State 1 receptors [52,56]. It remains unclear whether there are
two distinct receptor populations or, if not, exactly which factors deter-
minewhether a given ASGP-Rwill utilize the State 2 or the State 1 path-
way, although phosphorylation and palmitoylation of the receptor have
been implicated in these terms [52,57]. The ASGP-R has been shown to
play a vital role in host survival during a narrow range of severe inﬂam-
matory insults by clearing desialylated platelets and von Willebrand
factor (vWF), which accumulate in the serum under conditions of
sepsis induced by a neuraminidase expressing microorganism such
as Streptococcus pneumoniae [6]. This is a major, high-turnover pro-
cess for this receptor and, based on its mechanism, is presumably at-
tributable to State 2 recycling endocytosis activity. However, little
has been published to date regarding State 1 ASGP-R activity and
function, and the likelihood of an auxiliary role for this route during
inﬂammation has not yet been discussed.
The prevalent antibody immunoglobulin G (IgG) is known to associ-
ate in binding interactions with AP [200–203] and with the ASGP-R
[58–61]. We propose a mechanism in which liver AP, generated at the
hepatocyte canalicular membrane, is transported across the cell to the
basolateral membrane by the ASGP-R as an antigen in an IgG-bound im-
mune complex and secreted into the serum in a regulated manner as a
result of inﬂammation. This model does not involve paracellular transit
of AP or IgG, but rather requires the ASGP-R, through ‘rescue’ activity, to
mirror the behavior of IgG receptors like the neonatal Fc receptor (FcRn)
in other tissues by internalizing and transporting canalicular AP–IgG im-
mune complexes in response to a sufﬁcient inﬂammatory stimulus. Se-
cretion from the liver of such complexeswouldmake plasma-soluble AP
available to react with circulating PAMPs and DAMPs and subsequently
be encountered and processed by sinusoidal endothelial cells or macro-
phages. This processing by endothelial cells and macrophages may
provide an upstream signal for the induction of a number of anti-
inﬂammatory gene products, including AP itself. A hypothesis for such
a system is supported by abundant evidence regarding the characteris-
tics, individual binding and transport aspects, and relationships to in-
ﬂammation and to one another of AP, the ASGP-R, and IgG, which we
will present here.
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2.1. Expression, structure, and catalysis
In humans, there are four distinct AP isozymes (reviewed by
[20,62,63]): placental AP (PLAP), germ cell-type or placental-like AP
(GCAP), intestinal AP (IAP), and tissue non-speciﬁc AP (TNAP). The ge-
netic and post-translational glycosylation patterns of the different APs
vary considerably [62–85], but the cofactor requirements and mecha-
nism of AP catalysis are well conserved between isozymes [20,68,69].
In order to function, each monomer of an AP homodimer or
homotetramer binds two Zn2+ ions and one Mg2+ ion [20,62,69,70],
as well as one Ca2+ ion at a fourth metal-binding, non-catalytic site
[20]. The catalytic site in all APs is a single conserved serine residue
which is operational over a pH range of 6.5–10.5, encompassing the typ-
ical physiological span, but has optimal function at a notably alkaline pH
of 9–10.5 [20,26,47,71,120]. AP in general is thus capable of hydrolytic
phosphatase and transphosphorylase activity on a wide spectrum of
PAMP and DAMP substrates including LPS, ATP and ADP, and polyP
[20,24,30,31,63,69].
All APs are typically bound to the outer leaﬂet of the plasma mem-
brane of their cells of origin via a GPI linkage. In their membrane-
anchored form the enzymes tend to aggregate as tetrameric clusters
[62,86,87]. However, APs can also be freed from themembrane and cir-
culate in an anchorless, plasma-soluble, dimeric form, a process that oc-
curs much more efﬁciently for TNAPs than for PLAP or IAP [62,88–90].
Such a release of TNAP can occur by either of twomeans. TheGPI anchor
of the boundAPmay be cleaved at themembrane surface directly by co-
localized phospholipase C (PLC), though the activity of mammalian PLC
onGPI linkageswithout the aid of detergents is low [62,91]. Alternative-
ly, AP can separate from the cell together with its GPI linkage as an ini-
tially intact structure attached to small insoluble membrane vesicles, in
which case the anchor is subsequently cleaved by circulating phospho-
lipase D (PLD) to yield soluble AP [91–96]. It is the insoluble, vesicle-
associated form of AP that is found to be elevated in serum in many in-
ﬂammatory liver diseases [94,97].
Anchored liver AP is used as a canalicular membrane marker in he-
patocytes and is localized to relatively rigid sphingomyelin-rich patches
on that surface [81,98–100,105]. After exiting the trans-Golgi network
during the course of their biosynthesis in hepatocytes, newly synthe-
sized GPI-linked apical membrane proteins are routed to the basolateral
surface of the cell prior to being targeted to the canalicular membrane
by virtue of the apical sorting signal properties of either a key N-
glycan or the GPI linkage itself [81,96,101–104]. This is a default, unidi-
rectional transcytosis pathway for such proteins and it operates inde-
pendently of the common endocytosis mediator clathrin. Instead, this
basolateral endocytosis process for GPI-anchored proteins in hepato-
cytes is dependent on the scaffolding protein ﬂotillin-2 as well as the
large GTPase dynamin [101]. Such ﬂotillin-dependent internalization
pathways have slower kinetics than clathrin-dependent ones [101].
While liver AP has not been studied speciﬁcally in this regard, such a
transcytotic delivery pathway has been conﬁrmed for other GPI-linked
apical membrane markers in hepatocytes [101].
2.2. Negative feedback regulation of AP activity and nucleotide concentra-
tions at the canalicular hepatocyte surface
The apical localization of TNAP resulting from this transcytotic
process plays a vital role in the regulation of purine nucleotide catab-
olism and signaling at cell surfaces [20,45–47,106,107]. ATP in par-
ticular is present in baseline quantities under normal conditions
along the surfaces of many types of epithelial cells. Its hydrolysis
by ecto-ATPases is balanced by its intracellular production in high
concentrations (2–5 mM) and subsequent release from the cell.
Changes in extracellular concentrations of this nucleotide and its
dephosphorylated derivatives are key to regulating a number ofsignaling pathways [35,37,40,106,108–110]. Signal induction occurs
via ATP/ADP and adenosine binding to G-coupled P2X/P2Y and P1 re-
ceptors, respectively, at the surfaces of neighboring cells when ap-
propriate ligand levels surpass a threshold activation concentration
[34,107,109]. Interestingly, ATP in high concentrations can serve as
a DAMP in sterile liver inﬂammation by triggering inﬂammasome
formation through low-afﬁnity P2X receptor signaling [3,111], but
in lower concentrations it acts on the higher-afﬁnity P2Y receptor
subset, inducing immunosuppressive and tolerogenic responses
[111]. The extreme gradient between intracellular (mM) and extra-
cellular (nM) ATP concentrations facilitates a strong signal upon
even very small changes in the level of this nucleotide at the cell sur-
face [111]. Importantly, due to their higher afﬁnity, P2Y receptors
would likely respond ﬁrst to any changes in ATP concentration, and
immunosuppressive signalingmay prevail until amounts of extracel-
lular ATP reached the P2X activation threshold, inducing pro-
inﬂammatory signaling.
Though lysis is often responsible for the release of intracellular nu-
cleotides, hepatocytes also non-lytically secrete ATP, ADP, and AMP by
means of highly localized exocytosis into the extracellular space directly
adjacent to the apical surface. Here, the nucleotides, ATP in particular,
participate in autocrine and paracrine signaling activities with neigh-
boring hepatocytes as well as cholangiocytes lining the intrahepatic
bile ducts [33–37]. The observed non-uniform localization of vesicular
ATP release from hepatocytes suggests that there may exist special con-
ditions that are responsible for generating these point-bursts of high nu-
cleotide concentration [33,110]. Levels of extracellular ATP sufﬁcient for
signal transduction can be attained through a number of inﬂammatory
stimuli including LPS, hypoxia, increased cell volume, and mechanical
shear [33,35,109]. Particularly high concentrations of ATP can be
reached in the immediate vicinity of the plasma membranes of cells
with static surface layers like those of the airway, intestinal, and bile
duct epithelia, as opposed to in the bulk of extracellularﬂuid that bathes
these cells [35].
Released ATP can be dephosphorylated stepwise to adenosine at the
cell surface through the action of ectophosphatase enzymes (reviewed
in [40]). Adenosine binds to transmembrane P1 receptors and induces
a rise in intracellular cAMP levels [32,45,48,107]. This results in the acti-
vation of the cAMP-responsive cystic ﬁbrosis transmembrane conduc-
tance regulator (CFTR) Cl− channel in cells which express it, like
enterocytes, lung epithelial cells, and cholangiocytes, allowing for Cl−
efﬂux from the cell [37,45,46,48,106,107,110]. In cells such as hepato-
cytes which do not express CFTR, Cl− outﬂow occurs in response to
P2Y signaling induced by the original ATP rather than adenosine-
mediated P1 signaling, and it proceeds through a yet-unidentiﬁed chan-
nel that is distinct from the CFTR [45,46,48,107,110]. It has been sug-
gested that the responsible Cl− channel in these cells is Ca2+-
dependent [48,107]. This is logical because in the case of hepatocytes,
P2Y signaling causes a release of intracellular Ca2+ stores from the en-
doplasmic reticulum. This outﬂow of Ca2+ is mediated by the inositol-
1,4,5-triphosphate receptor (Ins3PR), which is localized near the cana-
licular membrane [112]. At lower ATP concentrations, P2Y stimulation
induces Ca2+ waves or oscillations in the form of repetitive concentra-
tion spikes; at higher ATP concentrations, a plateau of Ca2+ is observed
[113]. Such waveform Ca2+ release is polarized in the apical-to-
basolateral direction due to the pericanalicular localization of the
Ins3PRs and propagates downstream signals through information
encoded in the spatial and temporal patterns of the waves [112,114].
Some cells such as cholangiocytes are capable of both cAMP- and
Ca2+-mediated signaling pathways [107], but in either case, the com-
mon result is the generation of an anion gradient across the apicalmem-
brane. This drives controlled re-entry of Cl− into the cell in exchange for
the export of carbonic anhydrase-produced HCO3−, a process which in
hepatocytes is believed to be moderated by the anion exchanger 2
(AE2) transporter [48]. AE2 is localized to pericanalicular vesicles and
the canalicular membrane in hepatocytes as well as on the apical
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bile duct ligation, the apical localization of Ins3PRs and subsequently
Ca2+-drivenHCO3− secretion from rat cholangiocytes are lost, indicating
that Ca2+ wave polarity is required for proper HCO3− export [112,118].
This system provides for a HCO3−-driven pH gradient across the apical/
canalicular membrane and an alkaline environment external to the
cell at that surface [45,46,48].
Various tissue-speciﬁc purposes have been assigned to this alkalinity
in immediate proximity to the apical membrane. In cholangiocytes, it
has been implicated in the prevention of hydrophobicity-induced plas-
ma membrane disruption by ensuring bile salt deprotonation [45]. In
enterocytes, it is believed to protect the mucosa from sudden bursts of
acidity from the antecedent digestive tract [46], and in the airway, it
maintains surface liquid antimicrobial activity [119]. In all of these cell
types, at themolecular level, the basic pH of the epithelial surface is pre-
dicted to serve as a protectivemeasure against excessiveATP concentra-
tions leading to P2Y receptor overstimulation or P2X activation because
of the phosphatase activity of apically localized TNAP, which operates
optimally in just such alkaline conditions. This pH-moderated interplay
between TNAP and ATP appears to form a negative feedback loop in
these polarized cells in which rising extracellular ATP and subsequent
P2Y receptor activation lead stepwise to the increased alkalinization of
the apical/canalicular surface. Higher pH facilitates more efﬁcient activ-
ity of TNAP, which in turn dephosphorylates ATP, decreasing its concen-
tration and thus attenuating the P2Y signaling activity, diminishing
export of HCO3− and driving pH back down to maintain control of the
system [45–48,106].
3. The ASGP-R
3.1. Expression, structure, and binding
The human asialoglycoprotein receptor, expressed almost exclusive-
ly in the liver, is a recycling endocytotic lectin system composed of
heterooligomers of two subunits, the major subunit H1 and the minor
subunit H2. Both are necessary for high-afﬁnity association of the recep-
tor with ligand, and H1 andH2 are expressed in a ratio between 2:1 and
5:1 [52,121,122]. Each subunit contains a cytoplasmic domain, a single-
pass transmembrane domain, an extracellular stalk domain, and a
ligand-binding carbohydrate recognition domain (CRD) [52,123].
There are approximately 140,000 ASGP-R binding sites per cell in pri-
mary human hepatocytes and in HepG2 human hepatoma cells under
ordinary conditions [124,125]. Approximately 25–50% of these sites
are located on the basolateral hepatocyte surface, and the remainder
are distributed throughout the cell in membrane-bound vesicles
[52,55,126]. The ASGP-R, as introduced previously, has the capacity to
bind a wide variety of desialylated glycoproteins and is known to clear
them from circulation, transporting them to lysosomes for degradation
via a well-studied clathrin-mediated endocytosis pathway [6,51,52].
The receptor has a strong preference for binding tri- or tetra-
antennary ligands, primarily with N-acetylgalactose- and galactose-
terminated carbohydrate moieties [57,127]. Notably, however, the
ASGP-R is able to bind lactoferrin and IgG, both of which are known to
be involved with acute-phase immune activity, near its CRD with
surprisingly high afﬁnity given the sugar-independent nature of these
associations [52,59,128,129].
Ligand binding of a C-type lectin such as the ASGP-R is highly Ca2+-
dependent because interaction between the CRD and ligand requires di-
rect coordination of both to one of three Ca2+ ions, the accessibility of
which is inﬂuenced strongly by pH [50,52,127,130,131]. Themultiplicity
of Ca2+ coordination sites within the receptor allows each ASGP-R
subunit to bind to several ligands, forming a lectin–ligand binding lat-
tice [52,75]. The ASGP-R is thus extremely sensitive to pH, binding li-
gand exclusively above 6.0–6.5 [50,57,132], as well as to the geometry
of its ligands [52,130,133]. This facilitates receptor-speciﬁc regulation
of binding location and activity [127]. After binding at the basolateralsurface followed by endocytosis and sequestration into the sorting en-
dosome, dissociation of the receptor from its ligand takes place within
a specialized, mildly acidic endosome known as the compartment for
uncoupling of receptor and ligand, or CURL [134]. This dissociation is
generally believed to be mediated by the ASGP-R's pH dependence, al-
though an argument has been made for the role of structural modiﬁca-
tion of the receptor in this regard, speciﬁcally palmitoylation and
phosphorylation, since the CURL pH of ~6.0 is so near the receptor's
binding threshold [52].
ASGP-R function in hepatocytes diverges into two distinguishable
endocytosis pathways known as the State 1 and State 2 pathways
[52]. The State 2 ASGP-R pathway is the more active of the two under
standard conditions, processing approximately 80% of endocytosed li-
gand despite similar quantities and distributions of receptors in each
pathway. State 2 endocytosis has a ligand–receptor complex (LRC)
half life of ~2.5 min, undergoes constitutive receptor recycling, and
leads exclusively to lysosomal ligand degradation. In contrast, the less
active State 1 pathway has an LRC half life of ~50 min, does not consti-
tutively recycle receptors, and results in diacytosis of ligand back to the
original intake membrane in addition to a much slower rate of State 2-
like lysosomal degradation [52,57]. State 2 ASGP-Rs are dependent on
both pH and microtubule polymerization for motility, since they are
susceptible to, among other factors, interruption of pH gradients by
the ionophore monensin as well as administration of the microtubule
depolymerizing agent colchicine. In contrast, the State 1 pathway is
not signiﬁcantly affected by either of these treatments and is thus be-
lieved to be pH- and microtubule-independent [52].
In SK-Hep-1 hepatocellular carcinoma-derived endothelial cells
transfected with ASGP-Rs, roughly equivalent numbers of receptors
endocytosed the standard high-afﬁnity ASGP-R ligand asialoorosomucoid
(ASOR) via both clathrin-dependent and -independent pathways, the
latter of which has not been reported under standard conditions for
the ASGP-R in hepatocytes. The clathrin-dependent pathway in the
transfected cells followed the typical behavior pattern of the ASGP-R deg-
radative process. On the other hand, the clathrin-independent pathway
bypassed lysosomes, led to reappearance of ligand in the culturemedium
within 1 h, and was not pH-mediated. Importantly, this clathrin-
independent pathway was suggested to be a transcytotic trajectory for
the receptor in these polarized cells [57]. Under the proper circumstances,
then, the ASGP-R demonstrates clathrin-independent transcytotic activi-
ty which leads to exocytosis of ligand in a pH-independentmannerwith-
in a time frame corresponding to the LRC half life characteristic of State 1
ASGP-Rs in hepatocytes.
The characteristics that differentiate ASGP-Rs in the State 2 pathway
from those in the State 1 pathway have not been identiﬁed. H2 subunit
structural variation has been proposed as a basis for this distinction, as
there are three possible H2 subunits (H2a, H2b, andH2c) differing slight-
ly in amino acid content that can associate with H1 to form a functional
ASGP-R [52]. Cysteine (Cys) palmitoylation aswell as tyrosine (Tyr) and
serine (Ser) phosphorylation have also been implicated in receptor reg-
ulation [50,57,135–140].
Tyr5 of the H1 subunit's cytoplasmic domain is the key signaling res-
idue for basolateral sorting, recruitment to clathrin-enrichedmembrane
domains, and internalization of the ASGP-R [52,121,122,141–143].
When H1 Tyr5 residues are phosphorylated and ASGP-Rs are internal-
ized, high levels of extracellular ATP are able to reversibly ‘deactivate’
State 2, but not State 1, receptors [135,145]. ATP is required for ASGP-
R recycling, and ATP depletion within the hepatocyte redistributes a
portion of the ASGP-Rs from the basolateral membrane to intracellular
compartments. It also disrupts binding of typical desialylated glycopro-
tein ligands, but interestingly does not affect initial internalization of
surface receptors or the galactose-independent IgG binding previously
mentioned, which is a non-antigen–antibody interaction [59,146]. IgG
binds equally well to both ‘active’ and ‘inactive’ ASGP-Rs, so theoretical-
ly the antibody could still bind with high afﬁnity and be internalized
under conditions of elevated extracellular ATP, low intracellular ATP,
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rather than becoming non-functional in such circumstances, the
ASGP-Rmay instead actually be rerouted from State 2 to State 1 activity,
which could involve IgG uptake and may not be obvious in the absence
of an appropriate inﬂammatory stimulus.
Ser phosphorylation of the H2 subunit is another factor that may
play a role in determining the route taken by the ASGP-R within the
cell [52]. Treatment of HepG2 cells with phorbol esters leading to
ASGP-R cytoplasmic domain Ser hyperphosphorylation resulted in re-
distribution of basolateral receptors to intracellular locations, reminis-
cent of the effect of intracellular ATP depletion, but did not change the
total number of available binding sites [52,147].
Approximately 20% of intracellular ASGP-Rs are located within the
trans-Golgi network (TGN). This is a surprisingly high proportion, and
more than would be expected if this compartment were populated
only with de novo synthesized ASGP-Rs [52]. This suggests that the
ASGP-R recycles through the TGN, much like another basolaterally-
targeted, clathrin-dependent recycling receptor, the transferrin recep-
tor (TfR) [52,134,148]. Thismay provide a location for ASGP-R switching
between the State 2 and State 1 pathways, as may the sub-apical com-
partment, but details regarding this possible rerouting have not been
established [149–152].
3.2. The ASGP-R and inﬂammation
For many years after the ASGP-R's discovery, endogenous ligands
for the receptor remained unidentiﬁed. In 1994, the Galactosyl Homeo-
stasis Hypothesis was proposed, a model in which the ASGP-R is re-
sponsible for removing from circulation abnormal, potentially harmful
glycoconjugates generated under conditions like infection or tissue
damage [52,153] that lead to inﬂammation. The idea of an immune de-
fense function for the ASGP-R is supported by the fact that expression of
the receptor in hepatocytes does not take place in utero but rather oc-
curs rapidly following birth [6], like many other immune proteins
such as immunoglobulin A (IgA), which is generated upon post-natal
exposure to environmental antigens [154]. An immune role for the
ASGP-Rwas eventually conﬁrmedwhen it was observed that the recep-
tor mediated the clearance of desialylated glycoproteins including
asialo-platelets and asialo-von Willebrand factor, which circulate in el-
evated quantities during ﬁbrinolytic DIC induced by infection with
neuraminidase-expressing S. pneumoniae [6,51]. This is a process that
is presumably attributable to conventional State 2 recycling endocytotic
activity at the basolateral hepatocytemembrane. Under baseline condi-
tions, in the absence of inﬂammation or DIC, the ASGP-R was shown to
assist in regulating the homeostasis of circulating sialylated von
Willebrand factor (vWF) [6]. This coagulation factor is cleared primarily
by the liver sinusoidal endothelial cells (LSECs), but it also associates to
a lesser degree with hepatocytes [6].
Despite these observations, exposure to pro-inﬂammatory cytokines
like tissue necrosis factor alpha (TNFα), interferon-γ (IFγ), and
interleukin-2 (IL-2) has been shown to inhibit both carbohydrate-
mediated ligand binding to the ASGP-R and the receptor's mRNA ex-
pression in both HepG2 cells and primary rat hepatocytes, thereby actu-
ally discouraging clearance of circulating asialoglycoproteins by the
liver [50,155]. Also, upon infection with a non-sialidase expressing
strain of bacteria, the ASGP-R likely would not be able to play the
same role in acute phase glycoprotein clearance because the
sialylation states of vWF and platelets then would be unaffected.
Even if clearance of sialylated vWF would remain unchanged under
such circumstances, this activity is minor for hepatocytes in compar-
ison to LSECs. Importantly, however, ASGP-R receptor numbers in-
crease in primary human hepatocytes with no change in ligand
binding afﬁnity during ﬁbrosis, cirrhosis, and hepatocarcinoma
with cirrhosis [124]. Also, in contrast to the aforementioned observa-
tions, numbers of ASGP-R binding sites on HepG2 cell surfaces have
been seen to increase upon exposure to the pro-inﬂammatorycytokines TNF, IL-1, and IL-6, and receptor expression is enhanced
by 150%–180%, with its binding afﬁnity again remaining unaltered
[156]. This indicates that although the ASGP-R is involved in certain
cases with the removal of inﬂammation-related glycoproteins from
circulation, the receptor may have a different primary function
under general inﬂammatory conditions.
In support of this idea, as opposed to the intracellular receptor redis-
tribution seen with ATP depletion as mentioned, a full relocation of the
ASGP-R from the basolateral to the canalicular hepatocyte surface is
triggered by inﬂammatory insult like cirrhosis [50,157]. This suggests
the possibility of changes in ASGP-R ligand identity accompanying
changes in cellular localization under such conditions. The crucial
participation of the ASGP-R in the immune response of the liver during
inﬂammation has been demonstrated in vivo. Asgr1 knockout mice
show no obvious ill effects under normal conditions, but have more
glomerular ﬁbrin deposition and lower survival rates during S.
pneumoniae-induced sepsis and DIC compared to wild type counter-
parts [6]. This further exempliﬁes that the importance of ASGP-R func-
tion is not fully evident until the receptor is exposed to inﬂammatory
conditions. Collectively, these observations suggest that the ASGP-R
may be playing another role beyond glycoprotein clearance during the
course of inﬂammation and coagulopathy to render it essential to
survival.
4. Immunoglobulin G
4.1. Structure, function, and regulation
The answer to the question of what this role for the ASGP-R could be
may involve the well-studied immunoglobulin G (IgG) class of antibod-
ies, key contributors to the effector phase of the humoral immune sys-
tem. One widely known function of IgG relates to the maternal-to-
fetal transfer of immunity that occurs in humans across the placenta
to guard the fetus against infection until its own immune capacity is suf-
ﬁciently developed for defense in the post-natal period. The neonatal Fc
receptor (FcRn), a major histocompatibility complex (MHC) class I-
related receptor expressed by syncytiotrophoblastic cells in the placen-
ta, is responsible for actively transporting IgG frommaternal to fetal cir-
culation during the third trimester of gestation via transcytosis across
intact epithelia [158–161]. There are four subclasses of IgG available
for transport, known as IgG1, IgG2, IgG3, and IgG4. Naturally, as antibod-
ies, these IgGs vary in terms of the structure of their antigen-binding
fragments (Fab), but the subclasses also differ in their crystallizable frag-
ments (Fc), allowing for speciﬁc binding interactions with different re-
ceptors, carriers, and other molecules. FcRn ligand binding occurs
optimally between pH 5 and 6.5, and does not occur at standard physi-
ological pH or above. Therefore, the binding of IgG to the apical
syncytiotrophoblast surface that is observed experimentally at pH 7.4
is attributed to other receptors which are functional in higher pH condi-
tions, and FcRn-mediated IgG transport through the placental epithelia
is proposed to occur only after endocytosis by these other receptors, or
alternatively by ﬂuid-phase endocytosis, and subsequent delivery of
IgG to acidic endosomes, where the environment is more conducive
to FcRn binding [144,160,162]. Also, though FcRn is expressed in
syncytiotrophoblasts, it is not expressed in the villus endothelium, and
instead, the FcγRIIb receptor has been shown to be responsible for IgG
transport across this cell layer into the circulation after delivery to
endosomes [163].
Though this placental immune-transfer system in humans has been
well established, the relationship between IgG and FcRn is not limited to
this tissue or this pathway. Across neonatal rat intestinal epithelium, a
similar FcRn-mediated luminal-to-basolateral transcytotic mechanism
for delivery of IgG frommaternalmilk to neonate circulation is observed
[164–167]. The pH difference between the lumen (6.0) and the blood-
stream (7.4) is the driving force for this mechanism's unidirectional
transport, since the higher pH of the circulation prevents re-binding of
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halted in this tissue shortly after weaning, when passive transfer of im-
munity is no longer a necessity. In humans, however, FcRn expression
persists throughout adulthood in many epithelial and parenchymal tis-
sues including those of the intestine, lung, kidney, vascular endotheli-
um, and liver, and is believed to play an important role in the immune
defenses of these tissues due to its afﬁnity for IgG [167,168]. In many
of these tissues, IgG and FcRn undergo an antibody-preserving, pH-
sensitive, bidirectional transcytosis pathway in which FcRn sorts IgG
away from lysosomes, instead engaging in transport through the cell
resulting in exocytosis of intact IgG [159,164,166]. Human FcRn is
much more efﬁcient than rat FcRn in evading lysosomes [159,169]. It
has been shown that FcRn in human intestinal epithelium carries un-
bound IgG in a basolateral-to-apical direction from the circulation to
the lumen, but also transports the resulting luminal antigen-bound
IgG immune complexes in the apical-to-basolateral direction back to
the bloodstream for subsequent interaction with dendritic cells
[166,168,170]. In fact, FcRn binds better to multivalent IgG–antigen
complexes than to monovalent complexes or monomeric IgG
[166,169]. Such activity provides an immunosurveillance system for
mucosal epithelia in which circulating immune cells can sample, identi-
fy, and defend against speciﬁc pathogens at luminal surfaces on the
basis of antigen–IgG complexes.
In addition to transcytotic transport in either direction in polarized
epithelial cells, FcRn functions as a recycling receptor at and near the
cell surface [171–174]. It is responsible for taking up serum IgG and
also albumin, re-releasing both into circulation to protect them from a
degradative lysosomal fate. For this reason, IgG has an extremely suc-
cessful serum survival rate, circulating longer than any other protein
in the body and at concentrations nearing 10 mg/mL, reﬂecting its
value in the immune response [158,162,167,175,176]. In many cell
types expressing FcRn, like intestinal epithelium and vascular endothe-
lium, the receptor participates in both recycling and transcellular trans-
port; FcRn can thus switch between recycling and transcytotic
pathways. Importantly, however, FcRn expressed in hepatocytes has
been reported to undergo recycling only without a transcytotic compo-
nent to its itinerary [167].
The process of basolateral-to-apical transcytosis in polarized cells
has been well studied, with the polymeric immunoglobulin receptor
(pIgR) being used as a model protein for this trajectory, often
transfected into epithelial cell lines. No such exemplary system is
known for apical-to-basolateral transport, though, and the FcRn is typi-
cally used as a model since it is able to travel in this direction, albeit not
exclusively [168,177]. The pIgR transports polymeric immunoglobulin A
(pIgA) from the circulation to the lumen for antigen binding in many
cell types, including hepatocytes. The pIgR, like the ASGP-R, is relegated
by default to the basolateral membrane due to a sorting signal within its
cytoplasmic domain, and phosphorylation of Ser664 within this signal
disrupts this localization, inducing “ligand-stimulated transcytosis” of
the receptor to the apical pole upon IgA binding [177–179]. This is a
strictly unidirectional process, however. The bidirectional transcytosis
capability of FcRn in the absence of an appropriate pH gradient or
other stimulus for transport in one direction is an unusual feature that
is characteristic of this receptor.
Notably, apical-to-basolateral and basolateral-to-apical transcytosis
of IgG by FcRn appear to operate via distinct mechanisms, and Ser
phosphorylation within the recycling endosome is suggested to be a
key directionality determinant [159,180]. In inner medullary collecting
duct (IMCD) polarized epithelial cells from rat kidney, inhibition of FcRn
Ser313 phosphorylation has been demonstrated to abrogate transcytosis
in the apical-to-basolateral direction only, while basolateral-to-apical
transcytosis and receptor recycling are unaffected [159,181]. Also,
apical-to-basolateral transcytosis of IgG by FcRn in MDCK cells dis-
plays pH dependence but is microtubule-independent, although
transcytosis in the opposite direction does require intact microtu-
bules [182,183].4.2. IgG transport in the liver: FcRn vs. ASGP-R
In the liver, IgG is found in high concentrations in bile [180], as it is
along the mucosal surfaces of other tissues such as intestine, lung, and
genital tract [166]. Serum levels of IgG are often found to be elevated
in associationwith autoimmune hepatic diseases [184]. It has been pro-
posed that FcRn, which in rat hepatocytes has been shown to localize to
the canalicular membrane, may bind IgG–antigen immune complexes
in the bile and then deliver them transcellularly to the basolateralmem-
brane. Here, the complexes would be released and subsequently inter-
act with MHC class II-type receptors on nearby Kupffer cells [180].
Such immunosurveillance behavior would be consistentwith the previ-
ouslymentioned role of the FcRn in the intestine. However, the fact that
FcRn does not bind IgG at neutral or basic pH indicates that is not likely
to be well suited to IgG transport from the alkaline canalicular space.
Speciﬁcally, it has been demonstrated that FcRn binds IgG in rat hepato-
cytes below pH 6.5, but not at 8.0, the same pattern of pH dependence
that the enzyme displays in syncytiotrophoblasts, enterocytes, endothe-
lial cells, and polarized kidney cells, where rapid release of IgG occurs as
physiological pH is approached [159,160,168,174,183,185]. Also, since it
has been deduced, as mentioned previously, that FcRn does not carry
out its transcytosis mechanism in the liver [167,172,175], it seems un-
likely that this receptor could be responsible for IgG transport from
bile to circulation, so if immune complexes are being delivered
transcellularly to serum, it should be another receptor which serves as
a carrier.
Non-parenchymal cells of the liver, speciﬁcally LSECs and Kupffer
cells, have been demonstrated to be primarily responsible for the clear-
ance of circulating IgG immune complexes through FcRn-related Fcγ re-
ceptors (FcγR), with little to no help from hepatocytes [186–188,192].
Intravenously administered IgG immune complexes are taken up only
minimally at the basolateral membrane of hepatocytes, the vast major-
ity of the complexes being transported to the lysosomes of the pertinent
non-parenchymal cells [186,187]. LSECs in particular are known to
take up these immune complexes through the low-afﬁnity FcγRIIb re-
ceptor, which is not expressed by hepatocytes [186,189,190]. The
FcγRIIb receptor is a clathrin-dependent recycling endocytosis receptor,
expressed to some extent at the LSEC membrane but located primarily
(66%) intracellularly, and it is suspected to recycle constitutively
[186,191]. Intriguingly, FcγR and ASGP-R show differential binding af-
ﬁnity for the various IgG subclasses. In the placenta, the FcγR preferen-
tially binds IgG1 and IgG3 [193,194], whereas ASGP-R-associated IgG
subclasses in the liver are IgG2 and IgG4 despite the fact that normal
serum IgG is predominantly IgG1 [59]. This indicates that clearance of
IgG from circulation may not be the primary aim of its binding to the
ASGP-R. Circulating levels of IgG subclasses have been found to be insuf-
ﬁcient in patients with immunodeﬁciency syndromes, and IgG2 and
IgG4 shortages have been associated speciﬁcally with severe infections
[195], suggesting that theASGP-R-speciﬁc IgG subclassesmay play a dif-
ferent role in immunity than the other subclasses. In contrast to these
deﬁciencies, an elevation of IgG4 levels is commonly observed in IgG4-
related sclerosing cholangitis in the liver, which is often related to in-
ﬂammatory conditions like infection or malignancy. This elevation is
frequently accompanied by jaundice, though the biliary epithelium
tends to maintain its integrity [196]. This suggests that paracellular
transport is likely not responsible in this case for the inﬁltration into
serum of bile components.
IgG binds to the canalicularmembrane of freshly isolated rat hepato-
cytes at pH 6.0, but not pH 8.0 under baseline conditions [180]. This
points to FcRn involvement in liver IgG transport, since this receptor is
canalicularly localized in these cells and binds ligand at the pH indicat-
ed, and seemingly suggests that the ASGP-R, which is conﬁned to the
basolateral membrane and intracellular compartments under normal
circumstances and only binds ligand at pH N 6.0, could not be responsi-
ble for hepatic IgG transport from the bile. However, if FcRn does not
possess transcytosis activity in hepatocytes but only recycles IgG to
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complexes into serum. Also, we reason that the ASGP-R likely would be
able to gain access to IgG complexes in the bile when stimulated to
relocalize to the canalicular membrane, as the receptor is observed to
do in response to inﬂammatory insult like cirrhosis [50,157]. In this lo-
cation, the in vivo pH should be too high for FcRn binding, especially
under conditions of inﬂammation-induced elevated extracellular ATP
with concomitant HCO3− production and canalicular alkalinization, but
compatible with ASGP-R binding. In such a situation the ASGP-R could
theoretically play the role of FcRn, binding and internalizing canalicular
IgG immune complexes with speciﬁc antigens and lattice geometry.
Transcytotic mechanisms are uncommon, requiring a great deal of
coordination and energy, but the frequency with which they occur can
be ampliﬁedwith stimuli such as inﬂammation [197]. If the transcytotic
ASGP-R behavior described previously [57] were to be activated in he-
patocytes by ASGP-R-binding of IgG immune complexes, it could lead
to the release of IgG–antigen complexes into circulation followed by im-
mune cell uptake. Such transcytotic behavior is plausible in hepatocytes
given theputative involvement of Ca2+wave initiation near the canalic-
ular membrane in the previously mentioned negative feedback system
for the regulation of local pH and AP activity [45,48]. In this case, any
transcytotic activity of the ASGP-R, particularly involving transport of
immune complexes, likely would not be witnessed until initiated by
any number of inﬂammatory stimuli producing increases in extracellu-
lar ATP. Hence, we refer to such a process as ‘rescue ASGP-R activity’, or
R-ASGP-R activity.
It may be that State 2 ASGP-Rs lead to basolateral uptake and subse-
quent degradation of ligand and that State 1 receptors mainly serve the
purpose of transcytotic R-ASGP-R IgG immune complex transport, but
only under inﬂammatory conditions. In support of this idea, the State
1 ASGP-R pathway in hepatocytes is microtubule-independent [52], as
is apical-to-basolateral FcRn transport of IgG complexes in MDCK cells
[182,183]. The transcytosis pathway for ASGP-R was described to be
pH-independent, and State 1 ASGP-R activity is also pH independent
[52,57]. In addition, as mentioned earlier, ASGP-Rs have been observed
to shift from the basolateral membrane in response to inﬂammation,
moving to the canalicular membrane where IgG concentrations are
high [50,157,180]. IgG can bind with high afﬁnity and be internalized
by Tyr5-phosphorylated ASGP-Rs even in ATP-depleted hepatocytes,
where ASGP-R recycling activity is inhibited sharply by decreases in in-
tracellular ATP levels of 40% or more but the initial round of ASGP-R li-
gand binding and internalization is unaffected [146]. Since the FcRn can
switch between recycling and transcytotic pathways, the same may be
true for the ASGP-R despite the fact that it's usually regarded strictly
as a recycling endocytosis receptor. The recycling receptor TfR, which,
as previously mentioned, is well known to co-localize in intracellular
compartments and share behavioral similarities with the ASGP-R, can
be found in the same endocytic vesicles as FcRn, and a portion of the
TfR population actually can be compelled by sorting in the common en-
dosome to undergo FcRn-like bidirectional transcytosis [150,168,198].
This being the case, we reason that the same behavior may apply to
the ASGP-R, and that a fraction of the receptors could potentially be di-
rected into a transcytotic R-ASGP-R pathway.
4.3. IgG transport in the liver: AP
AP, speciﬁcally the PLAP isoform, has been shown to be involved
with the transport of IgG across the placenta for transfer of immunity
from mother to fetus, possibly behaving similarly to the FcRn [60,68].
However, while the occurrence of binding of PLAP to IgG is uncontested,
the enzyme's role speciﬁcally as an IgG carrier is debated [58]. It may be
that though PLAP is bound to the antibody, a distinct receptor is respon-
sible for IgG endocytosis and transcytosis. Levels of PLAP in the serum of
pregnant women and IgG in fetal serum increase steadily to high con-
centrations from 12 to 39 weeks of gestation [60,62,199]. IgG and AP
are believed to circulate as an immune complex, but evidence of thisis rarely seen in the laboratory due to harsh analytical conditions
disrupting the mild forces that maintain its integrity in vivo [60]. How-
ever, insoluble TNAP–IgG complexes have been detected in the serumof
patients with cancers, liver diseases, and autoimmune diseases
[71,97,200]. Other AP isozymes have also been found to associate with
IgG. Speciﬁcally, liver AP, expressed at the canalicular membrane of he-
patocyteswhere IgG concentrations are high, has been shown to bind to
the antibody in a sialylation-independent, non-hydrophobic manner at
the immunoglobulin's Fab region in an antigen–antibody interaction
with a 2:1 ratio [200–202]. Importantly, this association occurs in vivo,
but cannot be replicated in vitro with puriﬁed liver AP and polyclonal
IgG [71,201], indicating that other factors are likely involved with the
formation of such a complex. IAP has been shown to interact with IgG
in a similar fashion in the serum of patients with severe bacterial infec-
tions [71]. It has been suggested that a connecting protein may be in-
volved in the AP-IgG binding scenario since AP lacks a cytoplasmic tail
for the recruitment of adaptor proteins to itself [203].
Interestingly, APs in general share amino acid sequence similarity
with both collagen and vWF, the latter of which has been introduced al-
ready as an endogenous ASGP-R ligand under both baseline and inﬂam-
matory conditions [6,60,74,204]. Multimeric vWF is intimately involved
with primary hemostasis by binding to factor VIII (FVIII) along with
platelets and collagen, which, like the AP substrate ADP, is a potent
platelet activator [19]. This results in the formation of a platelet plug
in the early stages of clotting [8]. The region of AP which corresponds
to collagen and vWF is distinct from AP's catalytic domain. It is located
within AP's crown domain, which is near its Ca2+-coordination site,
and is easily accessible for binding [20,40]. This region contains a
highly-conserved Gly-Ala-Arg sequence and is proposed to participate
in binding interactions with other proteins, including collagen [74].
This is indicative of a possible role for AP in platelet plug formation, di-
rectly relating to aberrant hemostasis. If either subunit of the ASGP-R
can bind simultaneously to IgG aswell as a separate ligand at the lectin's
CRD [146], and liver AP can be a ligand for the ASGP-R as has been noted
[82], we speculate that the collagen/vWF-like region of the AP is in-
volved in this binding interaction and that the ASGP-R could associate
with each component of an antigen–antibody immune complex com-
prised of AP and IgG. This binding interactionmay require the coordina-
tion of the AP-associated Ca2+ ion with the Ca2+-dependent ASGP-R or
vice versa, and thus leave the AP catalytic site free for dephosphoryla-
tion activity. Liver AP–IgG complexes could form at the canalicular he-
patocyte membrane in response to inﬂammation, and ASGP-R arriving
at this location could then bind and transport them through the cell to
be released into circulation. In such a scenario, the ASGP-R would be
serving as the connecting protein in the AP–IgG system to provide cyto-
plasmic signaling opportunities within the cell.5. Summary: hypothesis for ‘rescue ASGP-R’ alkaline phosphatase
release mechanism
Based on the preceding foundation (summarized in Fig. 1), we pro-
pose the following possibility for an acute-phase R-ASGP-R AP transport
mechanism operating in the liver (Fig. 2). An undeﬁned inﬂammatory
insult slightly increases concentrations of ATP at the canalicular mem-
brane via non-lytic nucleotide release from hepatocytes. Concomitant
relocation of a portion of the ASGP-R population from the basolateral
to the canalicular membrane, possibly accompanied by receptor phos-
phorylation, occurs in response to the same inﬂammatory stimulus.
The subtle rise in extracellular ATP induces activation of high-afﬁnity
P2Y receptors. The alkaline pH generated at the immediate canalicular
surface by the P2Y-mediated ATP-AP negative feedback loop is likely
conducive to the binding of liver AP–IgG antigen–antibody complexes
in a lattice to multiple ASGP-Rs. As a downstream result of the P2Y sig-
naling cascade with its attendant directed Ca2+ wave induction, apical-
to-basolateral transcytosis of the loaded ASGP-Rs occurs, probably in a
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Fig. 1. Schematic summarizing the links betweenAP, IgG, ASGPR, and inﬂammation and coagulopathy.Wepropose thatAPplays a key role inpreventionof coagulopathy andpro-inﬂammatory
signaling, likely bydamping inﬂammatory signals bydephosphorylation aswell as by triggering its ownanti-inﬂammatory signaling cascade. Theprimary functionof anR-ASGP-R systemcould
be to deliver AP to the circulation to diminish pro-inﬂammatory signals and promote anti-inﬂammatory signals. In this case, APwould be an appealing therapeutic agent for the treatment of a
wide range of inﬂammatory and coagulopathic disease states, such as SIRS, sepsis, I/R injury, thrombosis/ischemic stroke/pulmonary embolism, edema, and autoimmune diseases. 1 refers to
reference [205].
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spond to State 1 ASGP-R activity.
Vesicles containing immune complex-bound ASGP-Rs secrete their
AP–IgG cargo into the serum upon cleavage of the AP GPI anchor by
PLD. Due to small quantities of bicarbonate transported from the cana-
licular space in conjunction with these complexes, the local pH is sufﬁ-
ciently basic for enhanced AP activity upon release, and the enzyme can
rapidly and effectively catalyze dephosphorylation of circulating LPS,
ATP/ADP, and polyP, among other potential PAMPs and DAMPs, thereby
diminishing pro-inﬂammatory signaling and coagulopathy. The AP–IgG
complexes can then be cleared through receptors like FcγRIIb or scaven-
ger receptors on surrounding non-parenchymal cells and circulating
immune cells to induce an anti-inﬂammatory response prior to complex
degradation. As a result of these events, increases in circulating levels of
pro-inﬂammatory cytokines like TNFα and IL-6 are prevented and the
body has additional time to mount a source-speciﬁc immune defense.
In this case, liver AP would be serving as a source-nonspeciﬁc antigen
to indicate the presence of an unidentiﬁed potential threat and induce
a proactive anti-inﬂammatory response, providing the immune system
with support during the time needed to specify the nature of the PAMP
or DAMP causing the inﬂammation and to develop an appropriatedefense. Secreted APmay ormay not also participate in binding interac-
tions with collagen or collagen-associated proteins to affect clot forma-
tion directly. As AP is transported away from the canalicularmembrane,
its expression in the hepatocyte is upregulated to replenish the supply
in an attempt to keep canalicular ATP levels in check. If the R-ASGP-R
system is overwhelmed by prolonged or worsening inﬂammatory in-
sult, extracellular ATP concentrations become sufﬁcient to induce pro-
inﬂammatory signaling via low-afﬁnity P2X receptor activation, and
PAMPs and DAMPs escaping dephosphorylation act according to their
various pro-inﬂammatory agendas.
We reason that the addition of exogenous AP to such a systemwould
not only increase the rate of PAMP and DAMP dephosphorylation in cir-
culation, but also result in soluble AP binding as an antigen to serum IgG,
speeding up the process of complex recognition by circulating immune
cells and providing the R-ASGP-R surveillance systemwith a ‘head start’
prior to secretion of endogenous liver AP. If this is the case, clinical ad-
ministration of AP may be an appealing treatment option for the pre-
vention of SIRS, sepsis, ischemia/reperfusion injury, inﬂammatory liver
disease, ischemic stroke, pulmonary embolism, atherosclerosis, edema,
Alzheimer's disease, multiple sclerosis, rheumatoid arthritis, and a
host of other inﬂammatory and coagulatory disease states. Our group
Fig. 2. Proposed mechanism for acute-phase ‘rescue ASGP-R’ activity induced by inﬂammatory insult. An inﬂammatory stimulus causes non-lytic nucleotide release from hepatocytes,
resulting in slightly elevated levels of extracellular ATP, as well as relocation of a portion of ASGP-Rs to the canalicular membrane. The ATP binds to high-afﬁnity surface P2Y receptors,
indirectly increasing alkalinity in the vicinity of the membrane via Ca2+ release from intracellular stores and Cl−/HCO3− exchange through AE2 transporters. This facilitates AP activity,
which controls ATP concentrations in a negative feedback loop. Immune complexes consisting of membrane-bound AP and bile IgG can bind in a lattice to multiple available ASGP-Rs
under the local pH conditions. The ASGP-Rs then transport the complexes along a Ca2+ wave-directed transcellular trajectory to the sinusoidal membrane. Here, the complexes are re-
leased into circulation by PLD cleavage for AP-catalyzed dephosphorylation of PAMPs and DAMPs (P/D) followed by complex uptake by endothelial cells and macrophages, inducing
anti-inﬂammatory signaling pathways. As AP is secreted through this process, its expression is upregulated at the canalicular membrane to maintain ATP concentrations. When the R-
ASGP-R system is overwhelmed, extracellular ATP concentrations reach sufﬁcient levels for low-afﬁnity P2X receptor activation leading to pro-inﬂammatory signaling, increasing levels
of TNFα, IL-6, and other pro-inﬂammatory cytokines.
2052 A.F. Pike et al. / Biochimica et Biophysica Acta 1832 (2013) 2044–2056is currently working to determine the validity of such a model and to
elucidate further the anti-inﬂammatory role of AP as well as the mech-
anistic details underlying its de novo synthesis.
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